Skip to main content

Market Overview

Atreca Stock Hits 52-Week Low As Initial ATRC-101 Data In Solid Tumor Fails To Impress

Atreca Stock Hits 52-Week Low As Initial ATRC-101 Data In Solid Tumor Fails To Impress

Atreca Inc (NASDAQ: BCEL) stock is hovering at a 52-week low after it announced initial data from the dose-escalation portion of its ongoing Phase 1b trial evaluating ATRC-101 in select solid tumor types.

  • Twenty-six participants were dosed. Eight of the 20 participants (40%) evaluable experienced stable disease (SD), including four with tumor reduction observed. 
  • The remaining 12 participants had progressive disease. 
  • Disease control observed in the study was associated with target expression.
  • Three of six (50%) of participants with evaluable response assessments and baseline tumor H-scores over 50 achieved SD, compared with 1 of 9 (11%) evaluable participants with an H-score below 50.
  • Expansion of peripheral blood CD8+ T cells was observed on day eight following dosing with ATRC-101. 
  • The Company will report additional data from monotherapy dose-expansion cohorts in the Phase 1b trial and combination cohorts with pembrolizumab in 2022.
  • Price Action: BCEL shares are down 34.9% at $5.35 during the market session on the last check Thursday.

Related Articles (BCEL)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Short Ideas Health Care Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at